ASPIVIX partners with Bayer Switzerland to reduce pain of gynaecological procedures
ASPIVIX’s ‘Carevix’ - a CE-Marked soft-suction cervical stabiliser is designed to minimise pain and bleeding during transcervical procedures, including IUD placement.
The traditional ‘forceps-like’ tenaculum is a big reason for the pain, discomfort and bleeding women experience during uterine procedures such as IUD insertion.
Now ASPIVIX - makers of a gentler alternative to the tenaculum - is teaming up with Bayer (Schweiz) AG in Switzerland to reduce the pain of gynaecological procedures.
Together the partnership will introduce ASPIVIX’s ‘Carevix’ - a CE-Marked soft-suction cervical stabilizer is designed to minimise pain and bleeding during transcervical procedures, including IUD placement.
This Swiss collaboration combines Bayer’s expertise in contraceptive solutions with ASPIVIX’s commitment to modernising gynaecology. Bayer is a globally recognised leader in women’s health solutions and is one of the world’s top producers of IUDs.
Announcing the partnership Bayer and ASPIVIX said:
“Our shared goal is to offer women a more comfortable and efficient gynaecological experience, reducing the cases of pain associated with IUD procedures.”
Reducing the pain of IUD insertion
The potential pain during IUD insertion impacts million women worldwide, largely due to the use of the century-old cervical tenaculum in gynaecological procedures.
Carevix, the suction cervical stabiliser, provides a more appealing alternative to the currently available tenaculum, filling an important unmet need and has demonstrated clinical effectiveness in reducing both pain and bleeding.
ASPIVIX CEO, Mathieu Horras, said:
“ASPIVIX is excited to enter this partnership with Bayer (Schweiz) AG that truly emphasises the goal of empowering women to select the best contraceptive solution without worrying about potential pain and bleeding.
“The thorough research and clinical data behind Carevix guarantees a notable decrease in pain and bleeding, enhancing the experience of IUD adoption and placement, as well as various other gynaecological procedures for millions of women.”
Bayer’s patient-centered approach
This is not the first time that Bayer has committed to reducing the pain of birth control insertion. In December, it announced it was teaming up with Crossbay Medical Inc in the USA - bringing together Bayer’s range of hormonal intrauterine systems (IUs), with Crossbay’s innovative ‘CrossGlide’ technology. The Crossglide is a new way of inserting birth control that follows the shape of the cervix and improves the overall experience.
Commenting on the ASPIVIX partnership, Bayer Switzerland Women’s Healthcare lead, Marco Gierten, said:
“As a globally trusted brand, Bayer remains committed to advancing solutions that provide significant benefits to patients.”